Fast Market Research

Euromonitor International's Industrial reports provide a 360 degree view of an industry. The Industrial market report offers a comprehensive guide to the size and shape of the Made-up Textile Articles market at a national level. It provides the latest retail sales data, allowing you to identify the sectors driving growth. It identifies the leading companies, the leading brands and offers strategic analysis of key factors influencing the market - be they new product developments, packaging innovations, economic/lifestyle influences, distribution or pricing issues. Forecasts illustrate how the market is set to change.

BMI View: We believe that the factors supporting our bullish outlook for Thailand's construction sector in 2012 - namely, the implementation of flood prevention measures, robust building construction activity and conducive monetary conditions for construction - will spill over in 2013. Combined with increased access to infrastructure financing and a large pipeline of construction projects, we believe that construction real growth could reach 5.2% in 2013. However, we do not expect construction activity to increase as rapidly or as significantly as the Thai government expects. This is because of labour and material shortages, the country's deteriorating fiscal position, business environment issues and the potential for political turmoil.

Construction activity in Malaysia has continued to grow at an impressive rate, but we believe we are seeing signs that the current construction cycle has reached its peak. This outlook is primarily due to falling demand for residential and non-residential buildings, as well as financing and political risks in the infrastructure sector. Having said that, there remains robust interest in Malaysia's construction sector as the country's 10-year economic plan continues to present significant project opportunities. This has prompted us to re-evaluate our outlook for Malaysia's construction sector over the short-term, with our forecasts for construction real growth revised up to 9.1% in 2013 (previously 7.2%) and 6.5% in 2014 (previously 5.9%).

Accounting for one quarter of retail value sales of gum in 2012, Wrigley's 5 has emerged as a notable success story. Targeting an audience of 14-25-year-olds, the product has essentially gum through tech-savvy lifestyle positioning and stylised pack design. Befitting a brand that targets young consumers, 5 has a strong social media presence with over six million Facebook fans worldwide and over 495,000 fans of 5 Gum Australia & NZ. The success of Wrigley's 5 is partly due to its premium...

With leading indicators showing much-sought-after improvements in the Japanese economy, we believe the optimism following the regime change in Japan will help to drive a pickup in economic activity in 2013. As such, we have revised up our forecast for GDP to 1.4%, from a previous forecast of 0.9%. We have also revised up our forecast for private consumption, and now expect growth of 1.5% in 2013, up from our previous forecast of 0.6% but still much lower than the 2.3% recorded in 2012.

GlobalData has released its new PharmaPoint Drug Evaluation report, "Actonel (Osteoporosis) - Forecast and Market Analysis to 2022". Despite its maturity, the osteoporosis market is expected to undergo substantial change between 2012 and 2022. Most importantly, the 'gold-standard' bisphosphonates will lose patent protection by end-of-year 2013, flooding the marketplace with less expensive generic versions of these physician-preferred medications. Additionally, Eli Lilly's blockbuster Evista, the only available SERM in the US, will lose patent protection in 2014, flooding the market with yet more affordable generic options. Also during the forecast period covered by this report, osteoporosis drug development research will lead to the launches of a wave of novel anabolic drugs with greater efficacy and safety, causing a major market shift away from anti-resorptive drugs. The number of companies vying for patient share will shrink by as much as 50%, as established players exit the market or acquire smaller players. Lastly, the aging of the population in developed markets will result in a larger patient pool.

- "The Packaging of Retail Alcoholic Drinks in The US, 2007 to 2017"is a data only report providing extensive and highly detailed time series consumption data on primary and outer packaging in the market. - The report provides in-depth quantitative data on retail(i.e. off-trade) alcoholic drinks packaging, covering key segmentations such as pack material and type, closure material and type, outer and multi-pack information, for the latest financial year (current year) and the extreme ends of the historical and forecast periods. - Detailed tables and charts provide a comprehensive breakdown of packaging consumption to clearly establish market trends, packaging dynamics and future growth areas.

GlobalData has released its new PharmaPoint Drug Evaluation report, "Keppra (Epilepsy) - Forecast and Market Analysis to 2022". Epilepsy is a brain disorder characterized by spontaneously occurring and recurrent seizures. The market is heavily driven by the sales of antiepileptic drugs (AEDs) targeted at seizure reduction. The AED market is currently dominated by UCB's Keppra and GlaxoSmithKline's Lamictal. Although both drugs have experienced significant generic erosion, they form the mainstay of epilepsy treatment in the nine markets and will continue to have significant market share during the forecast period. Other key drugs include older generation AEDs such as Pfizer's Dilantin, Abbott's Depakote, and Novartis' Tegretol and Trileptal which still have significant usage due to their longevity in the market. However, the AED dominance landscape will continue to shift towards newer generation drugs particularly following the recent market entry of GlaxoSmithKline's Trobalt/Potiga and Eisai's Fycompa which both offer first-in-class mechanisms of action.

Indonesia is set to see a surge in petrochemicals volumes in the short-to-medium term amid growing investor interest in this fast-growing market. However, we warn that declining oil production and a restricted refining base could undermine naphtha feedstock supplies. Furthermore, imports will continue to take up an increasing share of the market as supply struggles to keep up with demand.

Global Markets Direct's, 'B-Cell Lymphomas - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for B-Cell Lymphomas, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for B-Cell Lymphomas. B-Cell Lymphomas - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.